Literature DB >> 33666220

Type-2 diabetes, a co-morbidity in Covid-19: does insulin signaling matter?

Devanshi Mishra1, Chinmoy Sankar Dey1.   

Abstract

Type-2 Diabetes is associated with one of the co-morbidities due to SARS-Coronavirus 2 (SARS-Cov2) infection. Clinical studies show out of control glucose levels in SARS-Cov2 infected patients with type-2 diabetes. There is no experimental evidence suggesting aberrant molecular pathway(s) that explains why SARS-Cov2 infected patients with type-2 diabetes have uncontrolled glucose homeostasis and are co-morbid. In this article, we have highlighted major proteins involved in SARS-Cov2 infection, like, ACE 2, proteases like, TMPRSS2, Furin and their connectivity to insulin signaling molecules like, PI3K, Akt, AMPK, MAPK, mTOR, those regulate glucose homeostasis and the possible outcome of that cross-talk. We also raised concerns about the effect of anti-SARS-Cov2 drugs on patients with type-2 diabetes with reference to insulin signaling and the outcome of their possible cross-talk. There are no studies to decipher the possibilities of these obvious cross-talks. The major objective of this article is to urge the scientific community to explore the possibility of determining whether derangement of insulin signaling could be one of the possible causes of the patients with type-2 diabetes being co-morbid due to SARS-Cov2 infection.
© 2021 The Author(s). Published by Portland Press Limited on behalf of the Biochemical Society.

Entities:  

Keywords:  Covid-19; co-morbidity; insulin signaling; type-2 diabetes

Year:  2021        PMID: 33666220     DOI: 10.1042/BST20201062

Source DB:  PubMed          Journal:  Biochem Soc Trans        ISSN: 0300-5127            Impact factor:   5.407


  5 in total

1.  On virus and nanomaterials - Lessons learned from the innate immune system - ACE activation in the invertebrate model Enchytraeus crypticus.

Authors:  M J B Amorim; S I L Gomes; R C S Bicho; J J Scott-Fordsmand
Journal:  J Hazard Mater       Date:  2022-05-18       Impact factor: 14.224

2.  Safety and efficacy of a Siddha Medicine fixed regimen for the treatment of asymptomatic and mild COVID-19 patients.

Authors:  M Kannan; P Sathiyarajeswaran; D Sasikumar; A Geetha; M Mohanapriya; N P Vinod; P Manickam; K Kanakavalli; P Parthibhan; M Pitchiah Kumar; R Kannan; G Sivaraman
Journal:  J Ayurveda Integr Med       Date:  2022-05-23

Review 3.  Azithromycin: Immunomodulatory and antiviral properties for SARS-CoV-2 infection.

Authors:  Mohammad Rafi Khezri; Naime Majidi Zolbanin; Morteza Ghasemnejad-Berenji; Reza Jafari
Journal:  Eur J Pharmacol       Date:  2021-05-17       Impact factor: 5.195

4.  Impaired Glucose-Insulin Metabolism in Multisystem Inflammatory Syndrome Related to SARS-CoV-2 in Children.

Authors:  Valeria Calcaterra; Pietro Bosoni; Dario Dilillo; Savina Mannarino; Laura Fiori; Valentina Fabiano; Patrizia Carlucci; Elisabetta Di Profio; Elvira Verduci; Chiara Mameli; Gloria Pelizzo; Elena Zoia; Lucia Sacchi; Cristiana Larizza; Gianvincenzo Zuccotti
Journal:  Children (Basel)       Date:  2021-05-13

Review 5.  COVID-19 infection, progression, and vaccination: Focus on obesity and related metabolic disturbances.

Authors:  Annemarie J F Westheim; Albert V Bitorina; Jan Theys; Ronit Shiri-Sverdlov
Journal:  Obes Rev       Date:  2021-07-16       Impact factor: 10.867

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.